AlphaQuest LLC Raises Holdings in Tyra Biosciences, Inc. $TYRA

AlphaQuest LLC grew its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 146.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,073 shares of the company’s stock after buying an additional 43,451 shares during the period. AlphaQuest LLC’s holdings in Tyra Biosciences were worth $699,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of Tyra Biosciences by 50.5% during the 1st quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after buying an additional 1,823 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Tyra Biosciences during the 1st quarter worth about $84,000. Public Employees Retirement System of Ohio purchased a new stake in Tyra Biosciences during the 2nd quarter worth about $177,000. American Century Companies Inc. lifted its holdings in Tyra Biosciences by 5.8% during the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares in the last quarter. Finally, Jump Financial LLC lifted its holdings in Tyra Biosciences by 84.4% during the 1st quarter. Jump Financial LLC now owns 27,949 shares of the company’s stock worth $260,000 after purchasing an additional 12,789 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Up 4.3%

Shares of Tyra Biosciences stock opened at $14.84 on Tuesday. The firm has a market capitalization of $790.97 million, a PE ratio of -8.34 and a beta of 1.11. The business’s 50-day moving average price is $13.02 and its 200-day moving average price is $11.06. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $22.64.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.06. As a group, analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TYRA. Oppenheimer reissued an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Raymond James Financial began coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective on the stock. Wall Street Zen raised Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, October 4th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, August 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.